Acrivon Therapeutics Launches to Advance Clinical Oncology globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
DNAtrix to Present at the Raymond James Human Health Innovations Conference
News provided by
Share this article
Share this article
HOUSTON, June 9, 2021 /PRNewswire/ DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that the company will present at the Raymond James Human Health Innovations Conference on Monday, June 21, 2021, at 1:20 pm ET.
A live webcast of the presentation is available for access in the Newsroom section of DNAtrix s website at https://www.dnatrix.com/newsroom/. An archived replay of the presentation will be available for 30 days following the day of the event.
About DNAtrix
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company s lead product candidate is DNX-24
/PRNewswire/ Squaretalk, a global interactive business communications platform, has announced their partnership with SaaS giant Zoho Corporation. Squaretalk.
Share this article
Share this article
HOUSTON, March 4, 2021 /PRNewswire/ DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced the treatment of the first patient in a Phase 1 dose-escalation and dose-expansion study of DNX-2440, an OX40 ligand encoding oncolytic adenovirus, in patients with resectable liver metastasis. Expression of OX40 ligand on the surface of tumor cells is expected to enhance anti-tumor immune responses by providing costimulatory signals to T cells within the tumor microenvironment. We are excited to clinically explore the potential of one of our immunotherapy drug candidates, which is based on our proprietary adenovirus platform technology, in additional cancer indications, said Jeffrey Knapp, chief executive officer of DNAtrix. Our preclinical work with DNX-2440 has demonstrated that infection of human tumor cell lines with this agent leads to viral replication, high level expression of OX40 ligand on tumor cell
Press release content from Business Wire. The AP news staff was not involved in its creation.
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
February 1, 2021 GMT
FOSTER CITY, Calif. & EMERYVILLE, Calif. (BUSINESS WIRE) Feb 1, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection.